EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

From Epigenetic Dysregulation to Therapeutic Reprogramming in Endometrial Cancer: A State–Response Framework for Treatment Resistance

Manyata Srivastava, Shishir Singh, Pratik Kumar iD, Neha Moond, Ankita Chouhan, Komal Mann, Sarita Kumari iD, Monisha Banerjee, Atar Singh Kushwah iD

International Journal of Molecular Sciences · 14.05.2026 · 27 (10) · 4371

DOI: 10.3390/ijms27104371 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 14.05.2026. Verfasst von Manyata Srivastava und 8 weiteren Autor:innen. Beteiligte Einrichtung: Translational Oncology & Women's Health, Department of Biosciences, Manipal University Jaipur, Jaipur 303007, India. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Epigenesis, Genetic, Drug Resistance, Neoplasm, Cellular Reprogramming. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Science and Technology, Manipal University Jaipur.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Endometrial cancer (EC) is increasingly recognized as a heterogeneous disease, yet current treatment strategies often fail to explain why tumors with similar molecular profiles respond differently or develop resistance. This gap points to regulatory mechanisms beyond static genomic alterations. Epigenetic dysregulation through DNA methylation, histone modification, and non-coding RNA (ncRNAs) networks acts as a dynamic and reversible system that governs how tumors adapt under therapeutic pressure. In EC, alterations affecting key regulators such as MLH1, PTEN, and hormone receptors directly influence sensitivity to immunotherapy, targeted therapy, and endocrine treatment, defining treatment-responsive and treatment-resistant states. These observations shift the role of epigenetics from a descriptive feature of tumor biology to a determinant of therapeutic behaviour. Epigenetic states influence immune recognition, pathway activation, and cell cycle control, thereby shaping response to chemotherapy and immune checkpoint blockade. Biomarkers derived from these alterations, including methylation signatures and circulating RNAs, offer opportunities for patient stratification and longitudinal monitoring of treatment response. Therapeutically, targeting epigenetic regulators provides a strategy to reverse resistance and restore treatment sensitivity. DNA methyltransferase and histone deacetylase inhibitors, particularly in combination with established therapies, have shown potential to enhance treatment efficacy. Emerging approaches, including locus-specific epigenetic editing and liquid biopsy–guided monitoring, further support adaptive treatment strategies. Integrating epigenetic reprogramming into clinical decision-making offers a practical path toward improving treatment response and overcoming resistance in EC. Here, we propose an Epigenetic State–Response Framework (ESRF) in which dynamic epigenetic states define treatment-sensitive and resistant phenotypes, map to specific therapeutic vulnerabilities, and can be actively reprogrammed to restore treatment response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsEpigenesis, GeneticDrug Resistance, NeoplasmCellular ReprogrammingHumansFemaleDNA MethylationGene Expression Regulation, NeoplasticAnimalsImmunotherapyHistone Deacetylase Inhibitors

Stichwörter der Autor:innen

DNA methylationHDAC inhibitorsendometrial cancerepigenetic reprogrammingimmunotherapy sensitizationtherapeutic resistancetreatment response

Substanzen

Histone Deacetylase Inhibitors

Autor:innen und Institutionen

  • Translational Oncology & Women's Health, Department of Biosciences, Manipal University Jaipur, Jaipur 303007, India.
  • Division of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
  • Gynae Surgical Oncology, Max Institute of Cancer Care, Max Healthcare, Delhi 110075, India.
  • Molecular & Human Genetics Laboratory, Department of Zoology, University of Lucknow, Lucknow 226007, India.

ORCID-Profile: Pratik Kumar, Sarita Kumari, Atar Singh Kushwah

Förderung

  • Department of Science and Technology
  • Manipal University Jaipur

Zitieren

APA

Srivastava, M., Singh, S., Kumar, P., Moond, N., Chouhan, A., Mann, K., Kumari, S., Banerjee, M., & Kushwah, A. S. (2026). From Epigenetic Dysregulation to Therapeutic Reprogramming in Endometrial Cancer: A State–Response Framework for Treatment Resistance. International Journal of Molecular Sciences, 27(10), 4371. https://doi.org/10.3390/ijms27104371

Vancouver

Srivastava M, Singh S, Kumar P, Moond N, Chouhan A, Mann K, et al. From Epigenetic Dysregulation to Therapeutic Reprogramming in Endometrial Cancer: A State–Response Framework for Treatment Resistance. International Journal of Molecular Sciences. 2026;27(10):4371. doi:10.3390/ijms27104371

BibTeX
@article{Srivastava2026,
  author = {Srivastava, Manyata and Singh, Shishir and Kumar, Pratik and Moond, Neha and Chouhan, Ankita and Mann, Komal and Kumari, Sarita and Banerjee, Monisha and Kushwah, Atar Singh},
  title = {From Epigenetic Dysregulation to Therapeutic Reprogramming in Endometrial Cancer: A State–Response Framework for Treatment Resistance},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {10},
  pages = {4371},
  doi = {10.3390/ijms27104371}
}
Kostenlos starten →